2. Academic Validation
  3. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

  • Br J Haematol. 2015 Jul;170(1):134-8. doi: 10.1111/bjh.13278.
Yang Cao 1 2,  Guang Yang 1 2,  Zachary R Hunter 1 3 4,  Xia Liu 1 2,  Lian Xu 1,  Jie Chen 1,  Nickolas Tsakmaklis 1,  Evdoxia Hatjiharissi 3 4,  Sandra Kanan 1,  Matthew S Davids 1 2,  Jorge J Castillo 1 2,  Steven P Treon 5 6
Affiliations

Affiliations

  • 1 Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.
  • 2 Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • 3 Department of Pathology, Boston University Medical Center, Boston, MA, USA.
  • 4 Theagenio Cancer Hospital, Thessaloniki, Greece.
  • 5 Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA. [email protected].
  • 6 Department of Medicine, Harvard Medical School, Boston, MA, USA. [email protected].
PMID: 25582069 DOI: 10.1111/bjh.13278
Keywords

ABT-199; BCL2; CXCR4; Ibrutinib; Waldenström macroglobulinemia.

Figures
Products